Developmental Fluoxetine Exposure Facilitates Sexual Behavior in Female Offspring
Overview
Affiliations
Rationale: A growing number of infants are being exposed to selective serotonin reuptake inhibitor (SSRI) medications during the perinatal period. SSRIs target the serotoninergic system and are a popular treatment for maternal mood disorders. Serotonin itself plays a key role in the sexual differentiation through its role in the development of the hypothalamic-pituitary-gonadal axis, and previous research has shown that developmental SSRI exposure has an effect on sexual behavior in male offspring.
Objectives: Our aim was to determine the role of developmental exposure to a popular SSRI medication, fluoxetine, on sexual differentiation of the brain and behavior in female offspring using a rodent model of maternal adversity.
Methods: Stressed and non-stressed Sprague-Dawley rat dams were chronically treated with either fluoxetine (5 mg/kg/day) or vehicle beginning on postnatal day 1. Four groups of female offspring were used: (1) control + vehicle, (2) control + fluoxetine, (3) prenatal stress + vehicle, and (4) prenatal stress + fluoxetine.
Results: Primary results show that in adult female offspring, developmental fluoxetine exposure facilitates proceptive and receptive behaviors with a significant increase in the number of proceptive behaviors, a significant increase in the lordosis quotient, and a significant decrease in the rejection quotient.
Conclusions: This research contributes in the understanding of the long-term impact developmental fluoxetine exposure on the hypothalamus-pituitary-gonadal (HPG) system in adult female offspring.
Houwing D, Esquivel-Franco D, Ramsteijn A, Schuttel K, Struik E, Arling C Psychopharmacology (Berl). 2020; 237(9):2589-2600.
PMID: 32676774 PMC: 7501125. DOI: 10.1007/s00213-020-05535-7.
Antidepressant Use During Development May Impair Women's Sexual Desire in Adulthood.
Lorenz T J Sex Med. 2020; 17(3):470-476.
PMID: 31937517 PMC: 7197954. DOI: 10.1016/j.jsxm.2019.12.012.
Psychoactive drug exposure during breastfeeding: a critical need for preclinical behavioral testing.
Zucker I Psychopharmacology (Berl). 2018; 235(5):1335-1346.
PMID: 29549392 DOI: 10.1007/s00213-018-4873-0.
Gobinath A, Workman J, Chow C, Lieblich S, Galea L Biol Sex Differ. 2017; 8:20.
PMID: 28580124 PMC: 5454586. DOI: 10.1186/s13293-017-0142-x.
Environmental factors, epigenetics, and developmental origin of reproductive disorders.
Ho S, Cheong A, Adgent M, Veevers J, Suen A, Tam N Reprod Toxicol. 2016; 68:85-104.
PMID: 27421580 PMC: 5233640. DOI: 10.1016/j.reprotox.2016.07.011.